Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Shareholder Meeting (February 2025)
18 slides from Novo Nordisk A/s Class B's shareholder meeting presentation, Feb 27, 2025
Slide 1: Novo Nordisk
O a Novo nordisk
Slide 2: Annual General Meeting 2025
ANNUAL GENERAL MEETING 2025 Novo Nordisk A/S – Novo Alle 1, 2880 Bagsværd, Denmark – CVR no. 24256790 A Novo Nordisk employee receiving a tour of our active construction project at our site in Kalundborg, which is a part of our DKK 59 billion investment in new active pharmaceutical ingredient facili
Slide 3: The Board of Directors invites the shareholders to the 2025 Annual General Meeting
Annual General Meeting The Board of Directors invites the shareholders to the 2025 Annual General Meeting The Annual General Meeting of Novo Nordisk A/S (‘Novo Nordisk’ or the 'Company') will be held on Thursday 27 March 2025 at 14.00 (CET). The Annual General Meeting will be held as a partially ele
Slide 4: Participate or View Contact
Annual General Meeting / Agenda Participate or View 3 Contact Participate at the Annual General Meeting, in person or virtually: Request an admission card via the Investor Portal by Friday 21 March 2025 at 23:59 (CET) at the latest. Grant proxy or vote by correspondence: Fill in the proxy form by Fr
Slide 5: Elaboration on the items on the agenda
Annual General Meeting / Elaboration on the items on the agenda 4 Elaboration on the items on the agenda Item 5: Remuneration Item 5.1: Approval of the remuneration of the Board of Directors for 2024 The Board of Directors proposes that the actual remuneration of the Board of Directors for 2024 of D
Slide 6: Elaboration on the items on the agenda
Annual General Meeting / Elaboration on the items on the agenda 5 3 . For Board meetings and committee - related meetings held on another continent than the home country of the Board member, each member shall receive DKK 86 , 500 . The actual remuneration of the Board of Directors for 2025 will be p
Slide 7: Elaboration on the items on the agenda
Annual General Meeting / Elaboration on the items on the agenda 6 (c) The authority given to the Board of Directors under Articles 5.3(a) - (b) above can in the aggregate only be exercised to increase the share capital by a maximum nominal amount of DKK 44,650,000.” Item 8.3: Proposal from the share
Slide 8: Additional information
Annual General Meeting / Additional information 7 Additional information Majority requirements To adopt the proposal under item 8.2 of the agenda, at least two thirds of the total number of votes in the Company shall be present at the Annual General Meeting, and not less than two thirds of the votes
Slide 9: Additional information: how to participate
Annual General Meeting / Additional information 8 How to participate – participation in person, virtual participation or viewing the webcast Novo Nordisk offers three different ways for the shareholders to participate in or view the Annual General Meeting: • Participation in person. This includes th
Slide 10: Additional information
Annual General Meeting / Additional information 9 Simultaneous interpretation from English to Danish and from Danish to English will be available to in - person participants at Bella Center, virtual participants in the Computershare Meeting Services application as well as in the webcast . Informatio
Slide 11: Appendix - Candidates for the Board of Directors
Annual General Meeting / Appendix - Candidates for the Board of Directors Appendix Candidates for the Board of Directors Competences and experience to be represented on the Board (shareholder - elected Board members only) 10 Global corporate leadership Healthcare & Finance & accounting pharma indust
Slide 12: The individual candidates
Annual General Meeting / The individual candidates The individual candidates Helge Lund Chair Henrik Poulsen Vice chair Norwegian. Born October 1962. Male. Member since 2017. Term 2025. Chair of the Chair Committee and the People & Governance Committee. Helge Lund was also a member of the Board of D
Slide 13: The individual candidates (continued)
Annual General Meeting / The individual candidates The individual candidates (continued) Laurence Debroux Member of the Board 12 Andreas Fibig Member of the Board French. Born July 1969. Female. Member since 2019. Term 2025. Chair of the Audit Committee and member of the Remuneration Committee. Inde
Slide 14: The individual candidates (continued)
Annual General Meeting / The individual candidates The individual candidates (continued) Sylvie Grégoire Member of the Board 13 Kasim Kutay Member of the Board Canadian and American. Born November 1961. Female. Member since 2015. Term 2025. Member of the Audit Committee, the People & Governance Comm
Slide 15: The individual candidates (continued)
Annual General Meeting / The individual candidates The individual candidates (continued) Christina Law (full name: Choi Lai Christina Law) Member of the Board 14 Martin Mackay Member of the Board Chinese. Born January 1967. Female. Member since 2022. Term 2025. Member of the Audit Committee. Indepen
Slide 16: Employee-elected Board members
Annual General Meeting / Employee - elected Board members Employee - elected Board members are elected for a four - year term by the employees of Novo Nordisk A/S in Denmark. The most recent election of employee - elected Board members was conducted in February 2022, and the employee - elected Board
Slide 17: Employee-elected Board members
16 Annual General Meeting / Employee - elected Board members Danish. Born March 1972. Male. Member since 2018. Term 2026. Employee - elected board member. Member of the People & Governance Committee. Not independent Positions and management duties: Lead Auditor in Project Audits, Novo Nordisk A/S. C
Slide 18: Issued by Novo Nordisk A/S
Annual General Meeting 2025 issued by Novo Nordisk A/S – Novo Alle 1, 2880 Bagsværd, Denmark – CVR no. 24256790, +45 4444 8888 (switchboard), novonordisk.com SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its